UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): November 23, 2020
USA EQUITIES CORP.
(Exact Name of Registrant as Specified in its Charter)
0-19041
(Commission File No.)
Delaware | 30-1104301 | |
(State of Incorporation) |
(I.R.S. Employer Identification No.) | |
901 Northpoint Parkway Suite 302 West Palm Beach FL 33407 |
33407 | |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s telephone number, including area code: (929) 379-6503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, $0.0001 par value | USAQ | OTCMKTS |
Item 7.01 Regulation FD Disclosure.
On November 23, 2020, USA Equities Corp. (the “Company”) issued a press release announcing that the Company commenced revenue producing activities in the month of November 2020 shipping its first AllergiEnd test kits and patient immunotherapy treatment sets to numerous Physician customers.
A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website, press releases, and various social media channels, including its Twitter account (https://twitter.com/mpi_usaq), its LinkedIn account (https://www.linkedin.com/company/medicalpracticeincome/) its Facebook account (https://www.facebook.com/medicalpracticeincome), as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.
ITEM 9.01 Financial Statements and Exhibits
Exhibit No. | Description | |
99.1 |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: November 23, 2020 | ||
USA Equities Corp. | ||
/s/ Troy Grogan | ||
Name: | Troy Grogan | |
Title: | CEO and Chairman |
EXHIBIT 99.1
USA Equities Corp. (USAQ) Announces its First Shipment of Allergy Diagnostic & Treatment Products.
West Palm Beach, FL – November 23, 2020 – USA Equities Corp. (OTCQB: USAQ), and its wholly-owned subsidiary Medical Practice Income, a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce today that during the month of November the Company shipped its first revenue-producing allergy diagnostic and immunotherapy treatment products to its physician customers.
As previously disclosed, the Company entered into an exclusive distribution agreement with MedScience Research Group, Inc., a Florida Corporation (“MedScience”), whereby MedScience granted the Company an exclusive right to distribute its allergy diagnostic and allergen immunotherapy system named AllergiEnd® and related components (the “Products”) for sale to physicians.
“This is a significant milestone for USA Equities Corp indicating strong demand for our products and also is an indicator of our future success, given this sales milestone is ahead of recent analyst expectations for the Company’s growth position,” states Troy Grogan, President and CEO of USA Equities Corp.
About USA Equities Corp (OTCQB: USAQ)
On December 20, 2019, USA Equities Corp entered and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation located in West Palm Beach, Florida. As a result of the Share Exchange, MPI became our wholly owned subsidiary. We are focused on value-based healthcare solutions, clinical informatics, and algorithmically personalized medicine, including digital therapeutics, behavior based remote patient monitoring, chronic care, and preventive medicine. The Company’s intellectual properties, products, and information service portfolio focus on prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our objectives are developing proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address today’s obese, diabetic and cardiovascular disease population. For more information, visit www.MedicalPracticeIncome.com/discover.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp’s current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties, and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events, or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.
Investor Relations Contact: | |
Keith Pinder | |
Landon Capital | |
(404) 995-6671 | |
kpinder@landoncapital.net |